OnPoint

Welcome

OnPoint Analytics is an economic, finance and statistical consultancy specializing in expert testimony for complex, high-stakes litigation. The firm has been involved in many of the largest cases of the last decade. Although concentrations are heaviest in antitrust and competition, intellectual property, class certifications, pharmaceuticals and economic damages, we also provide services related to transition economies, the valuation of biodiversity, strategy, trade disputes, natural resources, the environment and renewable energy, insurance and healthcare, as well as financial analysis. Our experts include first rate academic economists and statisticians, as well as experts on franchises, business, finance, taxation and commercial real estate. A highly skilled staff of economists, statisticians, database architects and document analysts provide clients with tailored, empirically focused work product, accessible to the lay audience.


Pharma Corner blue

Biosimilar Conversion: How Slippery is the Slope?
Aug 21, 2015 – There is no doubt that massive capital has lined up behind biosimilar drug development. But there is less certainty about the extent to which biosimilars will capture the biologics market. Many commentators have predicted that biosimilars’ encroachment on branded biologics will be modest. Recent signs suggest that, once biosimilars enter the global market, they may quickly capture a significant share—the slope may be more slippery than expected.
To read the full text, click here.

 

Amgen v. Sandoz – Let’s Just Agree to Disagree
July 22, 2015 – Yesterday ended the long wait for the first appellate court interpretation of the 2010 Biologics Price Competition & Innovation Act. A 3-judge panel of the Federal Circuit (Lourie, Newman & Chen) struggled with arguably inconsistent language in the Act, which Judge Lourie described as “a riddle wrapped in an enigma.” OnPoint, specializing in pharmaceutical analytics and litigation, analyzes the economic ramifications of the decision for biosimilar drug development.
To read the full text, click here.

News black

OnPoint Experts Win Antitrust Writing Award

“Antitrust Class Proceedings – Then and Now,” an article co-written by OnPoint experts Gordon C. Rausser and Gareth J. Macartney, received a 2015 Antitrust Writing Award for Best Academic Article in the Private Enforcement category. The article, which was published last year in Vol. 26 of Research in Law and Economics, addresses the 2013 ruling in Comcast Corp. v. Behrend, 133 S. Ct. 1435, and its significance regarding the evolution of standards for reliable economic analysis in class certification.

The Antitrust Writing Awards are hosted by Concurrences Journal and George Washington University’s Competition Law Center. The Awards are intended to promote antitrust scholarship and competition advocacy by recognizing the best antitrust writing in the fields of law and economics. The winning articles—which were selected by a jury of academics, attorneys, and Concurrences readers—were announced at an April 14th gala dinner in Washington D.C.

To read the full text of the winning article, “Antitrust Class Proceedings – Then and Now,” click here.
To see a full list of 2015 Antitrust Writing Awards winners, click here.